JP4590504B2 - プロテアーゼ耐性ｆｌｉｎｔ類似体 - Google Patents

プロテアーゼ耐性ｆｌｉｎｔ類似体 Download PDF

Info

Publication number
JP4590504B2
JP4590504B2 JP2000608747A JP2000608747A JP4590504B2 JP 4590504 B2 JP4590504 B2 JP 4590504B2 JP 2000608747 A JP2000608747 A JP 2000608747A JP 2000608747 A JP2000608747 A JP 2000608747A JP 4590504 B2 JP4590504 B2 JP 4590504B2
Authority
JP
Japan
Prior art keywords
flint
analog
seq
amino acid
analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000608747A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002539829A (ja
JP2002539829A5 (enExample
Inventor
ラヴァンスクロフト，アドリアン，シー．
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2002539829A publication Critical patent/JP2002539829A/ja
Publication of JP2002539829A5 publication Critical patent/JP2002539829A5/ja
Application granted granted Critical
Publication of JP4590504B2 publication Critical patent/JP4590504B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
JP2000608747A 1999-03-30 2000-03-20 プロテアーゼ耐性ｆｌｉｎｔ類似体 Expired - Fee Related JP4590504B2 (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US12683999P 1999-03-30 1999-03-30
US14007399P 1999-06-21 1999-06-21
US60/140,073 1999-06-21
US14707199P 1999-08-04 1999-08-04
US60/147,071 1999-08-04
US16052499P 1999-10-20 1999-10-20
US60/160,524 1999-10-20
US16066999P 1999-10-21 1999-10-21
US60/160,669 1999-10-21
US17274499P 1999-12-20 1999-12-20
US60/172,744 1999-12-20
US17818400P 2000-01-26 2000-01-26
US60/178,184 2000-01-26
US60/126,839 2000-02-18
PCT/US2000/006418 WO2000058466A2 (en) 1999-03-30 2000-03-20 Protease resistant flint analogs

Publications (3)

Publication Number Publication Date
JP2002539829A JP2002539829A (ja) 2002-11-26
JP2002539829A5 JP2002539829A5 (enExample) 2007-05-24
JP4590504B2 true JP4590504B2 (ja) 2010-12-01

Family

ID=27568834

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000608747A Expired - Fee Related JP4590504B2 (ja) 1999-03-30 2000-03-20 プロテアーゼ耐性ｆｌｉｎｔ類似体

Country Status (8)

Country Link
EP (1) EP1165781B1 (enExample)
JP (1) JP4590504B2 (enExample)
AT (1) ATE371737T1 (enExample)
AU (1) AU3739500A (enExample)
CA (1) CA2368767C (enExample)
DE (1) DE60036199T2 (enExample)
ES (1) ES2291197T3 (enExample)
WO (1) WO2000058466A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
CA2277925A1 (en) 1997-01-14 1998-07-16 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6.alpha. and 6.beta.
ATE393222T1 (de) 1997-09-18 2008-05-15 Genentech Inc Dcr3 polypeptid, ein tnfr homolog
JP2002539828A (ja) * 1999-03-30 2002-11-26 イーライ・リリー・アンド・カンパニー Ｆｌｉｎｔポリペプチドアナログ
WO2001028582A2 (en) * 1999-10-20 2001-04-26 Eli Lilly And Company Therapeutic applications of flint polypeptides
EP1355945A2 (en) * 2001-02-01 2003-10-29 Eli Lilly And Company Flint glycoforms
AU2002246967A1 (en) * 2001-02-01 2002-08-12 Eli Lilly And Company Glycoforms a fas ligand inhibitory protein analog
EP1447093A1 (en) 2003-02-14 2004-08-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
EP3846829A4 (en) * 2018-09-05 2022-09-14 Arizona Board of Regents on behalf of Arizona State University ONCOLYTIC VIRUS PLATFORM FOR THE TREATMENT OF HEMATOLOGICAL CANCER

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2277925A1 (en) * 1997-01-14 1998-07-16 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6.alpha. and 6.beta.
ATE393222T1 (de) * 1997-09-18 2008-05-15 Genentech Inc Dcr3 polypeptid, ein tnfr homolog
CA2324517A1 (en) * 1998-03-30 1999-10-07 Eli Lilly And Company Therapeutic applications of mature flint (mflint) polypeptides or opg3, a member of the tnf receptor superfamily

Also Published As

Publication number Publication date
CA2368767A1 (en) 2000-10-05
JP2002539829A (ja) 2002-11-26
ATE371737T1 (de) 2007-09-15
EP1165781B1 (en) 2007-08-29
WO2000058466A2 (en) 2000-10-05
AU3739500A (en) 2000-10-16
WO2000058466A3 (en) 2001-01-11
DE60036199T2 (de) 2008-05-21
EP1165781A2 (en) 2002-01-02
CA2368767C (en) 2008-12-30
DE60036199D1 (de) 2007-10-11
ES2291197T3 (es) 2008-03-01

Similar Documents

Publication Publication Date Title
US20030129698A1 (en) Adipocyte complement related protein homolog zacrp7
JP2010213705A (ja) 線維芽細胞増殖因子様ポリペプチド
US7084253B2 (en) Protease-activated receptor PAR4 (ZCHEMR2)
JP2003506088A (ja) ＴＮＦリガンドスーパー遺伝子ファミリーの新規のメンバーであるＦｈｍ
JP4590504B2 (ja) プロテアーゼ耐性ｆｌｉｎｔ類似体
JP2002524039A (ja) ヒトアポプトシス阻害剤タンパク質ｈｉａｐ３をコードするｄｎａ
KR20070008510A (ko) 케모킨 변이체의 치료적 용도
US20030143671A1 (en) Novel beta-defensins
WO2000058465A2 (en) Flint polypeptide analogs
US6835814B1 (en) Protease resistant flint analogs
US6521233B1 (en) Adipocyte complement related protein homolog zacrp3
US20050048483A1 (en) Novel secreted proteins and their uses
JP3754299B2 (ja) 脂肪細胞補体関連タンパク質同族体ｚａｃｒｐ３
US6965012B1 (en) Flint polypeptide analogs
US7208578B2 (en) Adipocyte complement related protein homolog zacrp2
US7122342B1 (en) Protease-activated receptor PAR4 (ZCHEMR2)
JP2004041175A (ja) ヒトｌｉｇ−１相同体（ｈｌｉｇ−１）
EP1020521A1 (en) Fas Ligand inhibitor ( FLINT ) compositions and uses thereof
CA2378737A1 (en) Adipocyte complement related protein homolog zacrp5
CA2360584A1 (en) Mammalian alpha-helical protein - 12
US20040067504A1 (en) Adipocyte complement related protein zacrp8
EP1500663A1 (en) Secreted proteins and their uses
CA2358930A1 (en) Zsig67: a member of the human secretin-glucagon-vip hormone family
JP2007532092A (ja) 脂肪細胞補体関連タンパク質ｚａｃｒｐ１１

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070316

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100507

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20100521

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100521

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100706

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100730

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130924

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees